125 results
S-3ASR
EX-23.1
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the reference to our firm under the caption “Experts
S-3ASR
EX-5.1
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
in the Secretary’s Certificate and we have not undertaken any independent investigation or verification of the matters referred to in the Secretary’s
S-3ASR
AUTL
Autolus Therapeutics plc
28 Mar 24
Automatic shelf registration
4:10pm
. There are certain exceptions for trading in the United Kingdom through independent agents, such as some brokers and investment managers.
All … ended December 31, 2023 have been audited by Ernst & Young LLP (PCAOB ID: 01438), independent registered public accounting firm, as set forth
10-K
2023 FY
EX-10.12
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
in the [***] in the preceding Calendar Year.
10 1.104 “Gatekeeper” means a mutually agreed independent Third Party patent attorney. 1.105 “GLP” means … request to the other Party (the “Audited Party”), cause an internationally recognized independent accounting firm (which is reasonably acceptable
10-K
2023 FY
EX-23.1
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration
10-K
g7j0cyom
21 Mar 24
Annual report
4:55pm
10-K
EX-97.1
gqhqbqlt 169hzry0qb
21 Mar 24
Annual report
4:55pm
8-K
668 a4jhqlc
21 Mar 24
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K/A
EX-99.1
1k2 dndwm7ta
15 Mar 24
Results of Operations and Financial Condition
4:21pm
8-K
EX-99.2
ccgdi2w8uwv l69i
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
8od1xp16fx7voar4wrj
14 Mar 24
Results of Operations and Financial Condition
12:32pm
8-K
EX-99.1
rgjgbb6zyf
13 Feb 24
Regulation FD Disclosure
4:06pm
424B5
d0z3m33putq
9 Feb 24
Prospectus supplement for primary offering
5:15pm
8-K
EX-1.1
bj4d69plx4l16xku1ay
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
EX-5.1
w8euf
8 Feb 24
Autolus Announces Pricing of Underwritten Offering
4:17pm
8-K
x8wq9a5dv ma
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.1
aj559f8cx ueeu1
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
8-K
EX-10.3
8k3kc3 64ri6lx
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
S-3ASR
EX-5.1
5xa dpw3zhl
7 Feb 24
Automatic shelf registration
10:00pm
S-3ASR
qtrijgo377dp7ao
7 Feb 24
Automatic shelf registration
10:00pm